CLINICAL PHARMACOLOGICAL APPROACH TO THE USE OF ANTI-INFLAMMATORY DRUGS IN PREGNANCY
Keywords:
Pregnancy, anti-inflammatory drugs, NSAIDs, corticosteroids, clinical pharmacology, teratogenicity, fetal safety, maternal health, trimester-specific therapy.Abstract
This article examines the clinical pharmacological principles guiding the safe and evidence-based use of anti-inflammatory drugs during pregnancy. It focuses on the pharmacokinetic and pharmacodynamic changes occurring in pregnant women, the risk–benefit assessment of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and selective anti-inflammatory agents, as well as the potential fetal and maternal outcomes associated with inappropriate therapy. The paper also highlights current international recommendations, contraindicated drugs, trimester-specific considerations, and clinical monitoring strategies that ensure optimal therapeutic outcomes while minimizing teratogenic and obstetric risks.
References
Koren G., Nordeng H. Drugs in Pregnancy and Lactation. – London: Academic Press, 2019. – 412 p.
American College of Obstetricians and Gynecologists. Guidelines for Pharmacologic Treatment in Pregnancy. – Washington: ACOG Press, 2020. – 215 p.
Cimaz R., Brucato A. Corticosteroid use in pregnancy // Autoimmunity Reviews. – 2017. – Vol. 16(4). – P. 300–305.
Götestam Skorpen C., Hoeltzenbein M. et al. Biologic anti-inflammatory drugs and pregnancy // Annals of the Rheumatic Diseases. – 2016. – Vol. 75. – P. 795–810.
Østensen M., Motta M. Therapy insight: The effect of anti-inflammatory therapy on pregnant women with autoimmune diseases // Nature Clinical Practice. – 2006. – Vol. 2(7). – P. 488–494.
Sachs H. Pregnancy and drugs: Maternal and fetal considerations. – New York: Springer, 2018. – 328 p.
Saidkhodjaeva D. Farmakologiya asoslari. – Toshkent: “Fan va texnologiya”, 2021. – 264 b.
